Bizarre Patents
A sealed crustless sandwich for providing a convenient sandwich without an outer crust which can be stored for long periods of time without a central filling from leaking outwardly.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8187592 | C1-inhibitor prevents non-specific plasminogen activation by a prourokinase mutant without impeding fibrin-specific fibrinolysis A mutant prourokinase plasminogen activator (M5) was developed to make prouPA less subject to spontaneous activation during fibrinolysis. C1-inhibitor complexes with tcM5. The effect of C1-inhibitor on fibrinolysis and fibrinogenolysis by M5 was determined. Suppleme... | 05/29/2012 |
| 8182808 | Recombinantly modified plasmin Polynucleotides and polypeptides relating to a recombinantly modified plasmin(ogen) molecule are provided. The plasmin(ogen) molecule has a single kringle domain N-terminal to the activation site present in the native human plasminogen molecule, combined such that n... | 05/22/2012 |
| 8137666 | Nattokinase for degrading and reducing amyloid fibrils—associated with alzheimer's disease, prion diseases and other amyloidoses A method of dissolving or disrupting pre-formed or pre-deposited amyloid fibrils and/or inhibiting amyloid formation, deposition, accumulation, or persistence in Alzheimer's disease, prion diseases and/or other amyloidoses in a mammalian subject is disclosed. In the... | 03/20/2012 |
| 8124075 | Enhanced biological autologous tissue adhesive composition and methods of preparation and use The invention includes a composition useful for preparing a tissue sealant for use on a patient, comprising: autologous fibrinogen, an activating agent and at least one supplement. The invention includes a method of treating a disc having at least one defect, compri... | 02/28/2012 |
| 8088372 | Thrombin mutant A thrombin mutant in which at least serine at position 205 among amino acids in the active center of the thrombin B chain has been replaced with another amino acid, and further at least one of the following replacements have been introduced: (I) replacement of argin... | 01/03/2012 |
| 8071091 | Non-neurotoxic plasminogen activating factors for treating stroke The invention pertains to the use and production of non-neurotoxic plasminogen activating factors e.g. of Desmodus rotundus (DSPA) for the therapeutic treatment of stroke in humans in order to provide a new therapeutic concept for treating stroke in humans. | 12/06/2011 |
| 8071090 | Stabilized thrombin compositions Stabilized thrombin compositions, processes for preparing them, and kits comprising them are disclosed. The compositions comprise thrombin, a bacteriostatically effective amount of benzyl alcohol or chlorobutanol, and 0.10%-5.0% (w/v) sucrose in aqueous solution. Th... | 12/06/2011 |
| 7976837 | Method of preventing and treating brain infarction The present invention is intended to clarify the relationship between PAR-2 and cerebral infarction and thereby provide an efficient method of preventing and treating cerebral infarction, as well as a pharmaceutical composition therefore. Namely, the present inventi... | 07/12/2011 |
| 7947270 | Removing dental plaque with krill enzymes The invention relates to a multifunctional enzyme that can be derived from crustaceans or fish. The enzyme has at least one of a chymotrypsin, trypsin, elastase, collagenase and exo peptidase activity, and a molecular weight between about 20 kd and about 40 kd as de... | 05/24/2011 |
| 7939067 | Purified recombinant batroxobin with high specific activity A purified recombinant batroxobin with high specific activity, which has the following properties: (a) the batroxobin has a molecular weight of 29-32 kDa; (b) at least 90% of the batroxobin have 6 pairs of disulfide bonds which correctly match at Cys7-Cys... | 05/10/2011 |
| 7914783 | Pharmacological vitreolysis Methods of treating or preventing a disorder, or a complication of a disorder, of an eye of a subject, comprising contacting a vitreous and/or aqueous humor with a composition comprising a truncated form of plasmin comprising a catalytic domain of plasmin (TPCD) are... | 03/29/2011 |
| 7871608 | Reversibly inactivated acidified plasmin A method of treating a subject, the method including administring a composition that includes a reversibly inactivated acidfied plasmin substantially free of a plasminogen activator, in a low buffering capacity buffer, wherein the composition is a solution suitable ... | 01/18/2011 |
| 7867489 | Pharmacological vitreolysis A method of treating or preventing a disorder, or a complication of a disorder, of an eye of a subject comprising contacting a vitreous and/or aqueous humor with a composition comprising a truncated form of plasmin comprising a catalytic domain of plasmin (TPCD). TP... | 01/11/2011 |
| 7837992 | C-1 inhibitor prevents non-specific plasminogen activation by a prourokinase mutant without impeding fibrin-specific fibrinolysis A mutant prourokinase plasminogen activator (M5) was developed to make prouPA less subject to spontaneous activation during fibrinolysis. C1-inhibitor complexes with tcM5. The effect of C1-inhibitor on fibrinolysis and fibrinogenolysis by M5 was determined. Suppleme... | 11/23/2010 |
| 7691371 | Preparation comprising batroxobin for inhibiting local invasion of malignant tumors A preparation for inhibiting local invasion of malignant tumors is provided which comprises batroxobin and therefore can inhibit local invasion of malignant tumors. A preparation for encapsulating malignant tumor tissues is also provided which comprises batroxobin a... | 04/06/2010 |
| 7638123 | Methods of treating diseases with activated protein C Method of treating a disease or pathological condition with activated protein C or a compound having activated protein C activity by direct regulation of the expression of specific genes associated with the disease or pathological condition. ... | 12/29/2009 |
| 7632494 | Methods for enlarging the diameter of a biological conduit in a human subject The invention provides methods for treating an obstructed biological conduit that include administering to the conduit an agent that can degrade extracellular matrix of obstructing tissue. Particular methods include delivery of an enzyme or a mixture of several enzy... | 12/15/2009 |
| 7560107 | Modified factor VIII Modified porcine factor VIII is disclosed in which most of the B domain has been removed through genetic engineering. This modified factor VIII is particularly useful for treatment of hemophiliacs, especially those undergoing bleeding episodes. ... | 07/14/2009 |
| 7547435 | Pharmacological vitreolysis Methods of treating or preventing a disorder, or a complication of a disorder, of an eye of a subject, comprising contacting a vitreous and/or aqueous humor with a composition comprising a truncated form of plasmin comprising a catalytic domain of plasmin (TPCD) are... | 06/16/2009 |
| 7507403 | Kallikrein gene The invention relates to a kallikrein protein, compositions comprising the protein, and the use thereof. ... | 03/24/2009 |
| 7479270 | Methods and compositions for activating VEGF-D and VEGF-C Methods for activating endothelial growth factors VEGF-C or VEGF-D with plasmin, and methods of treatment comprising administering a phamarceutical compositions comprising plasmin. Also disclosed are methods for screening for inhibitors of activation of the growth f... | 01/20/2009 |
| 7459155 | Treating abdominal pain due to pancreatitis with seaprose This invention relates to methods for maintaining the basal level or reducing the level of cholecystokinin (CCK) in blood plasma of a mammal. Additionally, the invention provides methods for treating pain in a mammal and more particularly, methods for treating abdom... | 12/02/2008 |
| 7429377 | Therapeutic composition containing a plurality of immobilized proteases A pharmaceutical composition having thrombolytic, anti-inflammatory and cytoprotective properties is described. The composition contains active proteases attached to a gel or to a mixture of a gel with a water-soluble polymer, said attachment being achieved with the... | 09/30/2008 |
| 7425534 | Compositions and methods for modulating muscle cell and tissue contractility The present invention relates to compositions and methods comprising one or more domains of urokinase-type plasminogen activator (uPA) in an amount effective to modulate one or more of the contractility and angiogenic activity of a mammalian muscle or endothelial ce... | 09/16/2008 |
| 7423009 | Method for treatment of kidney diseases The present invention relates to a composition for prevention and treatment of kidney diseases comprising one or more effective component(s) of a PAR-2 activating agent which is able to activate PAR-2 and a pharmaceutically acceptable carrier. The present invention ... | 09/09/2008 |
| 7410638 | Bacterial strains, genes and enzymes for control of bacterial diseases by quenching quorum-sensing signals The present invention relates to isolated nucleic acid molecules encoding an autoinducer inactivation protein, wherein the encoded protein comprises an amino acid sequence selected from the group consisting of 104HXHXDH109˜60aa˜H169 | 08/12/2008 |
| 7407653 | Treatment of IgA1 deposition diseases The present invention discloses the use of bacterial IgA1 proteases to treat IgA1 deposition in tissue and organs. Bacterial IgA1 proteases specifically cleave IgA1 molecules and thus provide a means to specifically cleave and remove IgA1 depositions. Accordingly, t... | 08/05/2008 |
| 7407789 | Recombinant staphylokinase derivatives and the preparation and applications thereof The present invention relates to the biotechnology field, more particularly, to novel recombinant staphylokinase (RGD/KGD-Sak) derivatives and the preparation the thereof. The derivatives, have a low polymerizing ability, low immunogenicity and a bifunctionality of ... | 08/05/2008 |
| 7393528 | Biological pesticide Methods for exterminating pests using compositions comprising at least one protease enzyme. A detergent component may also be utilized in such compositions. ... | 07/01/2008 |
| 7364562 | Anti-clotting apparatus and methods for fluid handling system A method for maintaining clear passageways in an extracorporeal blood flow system. The method comprises intermittently providing one or more anti-clotting agents to a passageway of the extracorporeal blood flow system. Also disclosed is an extracorporeal blood flow ... | 04/29/2008 |
| 7364890 | Thermal tolerant avicelase from The invention provides a thermal tolerant (thermostable) cellulase, AviIII, that is a member of the glycoside hydrolase (GH) family. AviIII was isolated and characterized from Acidothermus cellulolyticus and, like many cellulases, the disclosed polypeptide an... | 04/29/2008 |
| 7361344 | Co-administration of a thrombolytic and an-anti-CD18 antibody in stroke A method for improving clinical outcome in focal ischemic stroke in a mammal by increasing cerebral blood flow and/or reducing infarct size is described which involves administering an effective amount of an anti-CD18 antibody to the mammal, in the absence of remova... | 04/22/2008 |
| 7361335 | Methods for using an elastase The invention provides methods for treating an obstructed biological conduit that include administering to the conduit an agent that can degrade extracellular matrix of obstructing tissue. Particular methods include delivery of an enzyme or a mixture of several enzy... | 04/22/2008 |
| 7351798 | Stabilized protein crystals, formulations comprising them and methods of making them This invention relates to methods for the stabilization, storage and delivery of biologically active macromolecules, such as proteins, peptides and nucleic acids. In particular, this invention relates to protein or nucleic acid crystals, formulations and composition... | 04/01/2008 |
| 7351561 | Thrombin preparations and process for their production The production of a thrombin preparation which is obtained from prothrombin which is, after activation to thrombin without the addition of thromboplastin, purified by a hydrophobic interaction chromatography, it being possible subsequently also to inactivate or remo... | 04/01/2008 |
| 7335351 | Immunotherapeutic methods targeted towards stratum corneum chymotryptic enzyme The present invention discloses the protease stratum corneum chymotrytic enzyme (SCCE) is specifically over-expressed in ovarian and other malignancies. A number of SCCE peptides can induce immune responses to SCCE, thereby demonstrating the potential of these pepti... | 02/26/2008 |
| 7332469 | Intrapleural single-chain urokinase alone or complexed to its soluble receptor protects against pleural adhesions The present invention relates to methods of preventing or decreasing the severity of scarring in a subject comprising: obtaining a pharmaceutical composition comprising a single chain urokinase plasminogen activator molecule (scuPA) or a scuPA mimetic; and administe... | 02/19/2008 |
| 7332320 | Protease producing an altered immunogenic response and methods of making and using the same The present invention provides novel protein variants that exhibit reduced immunogenic responses, as compared to the parental proteins. The present invention further provides DNA molecules that encode novel variants, host cells comprising DNA encoding novel variants... | 02/19/2008 |
| 7330236 | Exposure apparatus, and device manufacturing method using the same Disclosed is an exposure apparatus having a specific structure that includes a cold trap plate for attracting contaminant substances which might cause a decrease of reflectance of a mirror when adhered thereto, and a radiation shield member for preventing excessive ... | 02/12/2008 |
| 7326412 | Fibrinogen plus a non-plasmin-acting fibrinolysis inhibitor for the reduction or prevention of adhesion formation Reducing or preventing adhesions which would otherwise form in a patient during or after surgery by administering a fibrinogen preparation containing a non-plasmin-acting fibrinolysis inhibitor such as eglin. ... | 02/05/2008 |
